[1] Wang T H, Hsia S M, Shieh T M.Lysyl oxidase and the tumor microenvironment[J]. International Journal of Molecular Sciences, 2016, 18(1):62. [2] Almacellas-Rabaiget O, Monaco P, Huertas-Martinez J, et al. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity[J]. Cancer Letters, 2020, 474(474):1-14. [3] Xiao Q, Ge G.Lysyl oxidase, extracellular matrix remodeling and cancer metastasis[J]. Cancer Microenvironment, 2012, 5(3):261-273. [4] Cox T R, Erler J T.Lysyl oxidase in colorectal cancer[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2013, 305(10):G659-G666. [5] 梁金娥,王安琪,史煜,等.LOX家族在肿瘤中的研究进展[J].现代肿瘤医学,2019,27(20):3733-3736. LIANG J E, WANG A Q, SHI Y, et al. Research progress of LOX family in tumors[J]. Journal of Modern Oncology, 2019, 27(20):3733-3736. [6] 管雅喆,任萌,郭冬利,等. 肺癌筛查研究进展[J].中国肺癌杂志,2020,23(11):954-960. GUAN Y Z, REN M, GUO D l, et al. Research progress of lung cancer screening[J]. Chinese Journal of Lung Cancer, 2020, 23(11):954-960. [7] Xing P Y, Zhu Y X, Wang L, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China[J]. Cancer Medicine, 2019, 8(8):4055-4069. [8] Nilsson M, Adamo H, Bergh A, et al. Inhibition of lysyl oxidase and lysyl oxidase-like enzymes has tumour-promoting and tumour-Suppressing roles in experimental prostate cancer[J]. Scientific Reports, 2016, 6(6):19608. [9] Rachman-Tzemah C, Zaffryar-Eilot S, Grossman M, et al. Blocking surgically induced lysyl oxidase activity reduces the risk of lung metastases[J]. Cell Reports, 2017,19(4):774-784. [10] Gong C, Gu R, Jin H, et al. Lysyl oxidase mediates hypoxia-induced radioresistance in non-small cell lung cancer A549 cells[J]. Experimental Biology and Medicine (Maywood),2016,241(4):387-395. [11] 展平,谢海燕. 赖氨酰氧化酶样蛋白2在肺腺癌患者中的预后价值[J]. 肿瘤学杂志,2017,23(11):973-977. ZHAN P, XIE H Y.Prognostic value of lysyl oxidase-like protein 2 in patients with lung adenocarcinoma[J]. Journal of Oncology, 2017, 23(11):973-977. [12] Wilgus M L, Borczuk A C, Stoopler M, et al. Lysyl oxidase: a lung adenocarcinoma biomarker of invasion and survival[J]. Cancer, 2011, 117(10):2186-2191. [13] Liu J, Ping W, Zu Y, et al. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer[J].International Journal of Clinical and Experimental Pathology, 2014, 7(9):6040-6047. [14] Hou X, Du H, Quan X, et al. Silibinin inhibits NSCLC metastasis by targeting the EGFR/LOX pathway[J]. Frontiers in Immunology, 2018,9(9):21. [15] Lindskog C, Edlund K, Mattsson J S, et al. Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?[J]. Expert Review of Molecular Diagnostics, 2015, 15(4):471-490. [16] Lee G H, Kim D S, Chung M J, et al. Lysyl oxidase-like-1 enhances lung metastasis when lactate accumulation and monocarboxylate transporter expression are involved[J]. Oncology Letters, 2011, 2(5):831-838. [17] Le Calve B, Griveau A, Vindrieux D, et al. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution[J]. Oncotarget, 2016, 7(22):32100-32112. [18] Barker H E, Cox T R, Erler J T.The rationale for targeting the LOX family in cancer[J]. Nature Reviews Cancer, 2012,12(8):540-552. [19] Alsofi L, Daley E, Hornstra I, et al. Sex-linked skeletal phenotype of lysyl oxidase like-1 mutant mice[J]. Calcified Tissue International, 2016, 98(2):172-185. [20] Zeltz C, Pasko E, Cox T R, et al. LOXL1 is regulated by integrin alpha11 and promotes non-small cell lung cancer tumorigenicity[J]. Cancers (Basel), 2019, 11(5):705. [21] Hollosi P, Yakushiji J K, Fong K S, et al. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells[J]. International Journal of Cancer, 2009, 125(2):318-327. [22] Herranz N, Dave N, Millanes-Romero A, et al. Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3[J]. FEBS Journal, 2016, 283(23):4263-4273. [23] Ye M, Zhang J, Guo T, et al. MiR-504 inhibits cell proliferation and invasion by targeting LOXL2 in non-small cell lung cancer[J]. Biomedicine and Pharmacotherapy, 2018, 97(97):1289-1295. [24] Zhan P, Lv X J, Ji Y N, et al. Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer[J]. European Clinical Respiratory Journal, 2018, 12(2):712-720. [25] Mizuno K, Seki N, Mataki H, et al. Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma[J]. International Journal of Oncology, 2016,48(2):450-460. [26] Kamikawaji K, Seki N, Watanabe M, et al. Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis[J]. Journal of Human Genetics, 2016, 61(12):985-993. [27] Peng D H, Ungewiss C, Tong P, et al. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis[J]. Oncogene, 2017, 36(14):1925-1938. [28] Kasashima H, Yashiro M, Okuno T, et al. Significance of the lysyl oxidase members lysyl Oxidase like 1, 3, and 4 in gastric cancer[J]. Digestion, 2018, 98(4):238-248. [29] Sebban S, Golan-Gerstl R, Karni R, et al. Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer[J]. Clinical and Experimental Metastasis, 2013, 30(1):103-117. [30] Ye M, Song Y, Pan S, et al. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy[J].Pharmacology and Therapeutics, 2020, 215:107633. [31] 张晓春. 2019肺癌精准治疗的前沿与展望[J]. 医学研究生学报,2019,32(10):1009-1013. ZHANG X C.Frontier and prospect of precise treatment of lung cancer in 2019[J]. Journal of Medical Postgraduates, 2019, 32(10):1009-1013. [32] Zhang Y, Jiang W L, Yang J Y, et al. Downregulation of lysyl oxidase-like 4 LOXL4 by miR-135a-5p promotes lung cancer progression in vitro and in vivo[J]. Journal of Cellular Physiology, 2019, 234(10):18679-18687. [33] Xie S, Liu G, Huang J, et al. miR-210 promotes lung adenocarcinoma proliferation, migration, and invasion by targeting lysyl oxidase-like 4[J]. Journal of Cellular Physiology, 2019, 234(8):14050-14057. |